Premium
Novel biologic therapies in development targeting IL‐12/IL‐23
Author(s) -
Van De Kerkhof PCM
Publication year - 2010
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.2010.03830.x
Subject(s) - medicine , ustekinumab , psoriasis , placebo , dosing , interleukin 23 , clinical trial , dermatology , plaque psoriasis , interleukin 17 , disease , cytokine , pathology , infliximab , alternative medicine
Recent research has identified the importance of interleukin 12 (IL)‐12 and IL‐23 in the immunopathogenesis of psoriasis. The p40 subunit common to IL‐12 and IL‐23 is an attractive target for selective therapy. Clinical study data are available for two anti‐IL‐12/23 therapies: ustekinumab (CNTO 1275, approved in 2009 for treatment of plaque psoriasis) and ABT‐874. The Phase 3 clinical trials PHOENIX 1 and PHOENIX 2 have shown significant benefit for ustekinumab in moderate‐to‐severe plaque psoriasis, with PASI 75 response rates ranging from 66% at week 12 (after two injections) and rising to 85% at week 24 (after three injections). Withdrawal of treatment led to a gradual return of psoriasis whereas continued therapy every 12 weeks with ustekinumab maintained PASI 75 response. Analysis of safety data demonstrated a safety profile similar to placebo at week 12 and did not reveal any major safety concerns in blocking IL‐12 and IL‐23 for periods as long as 18 months. Phase 2 data indicate that ABT‐874 is also efficacious in the treatment of moderate‐to‐severe plaque psoriasis across a range of dosing strategies.